Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Ortopedisk forskningssenter, St.Olavs Hospital, Trondheim, Norway
Kingston General Hospital, Kingston, Ontario, Canada
Hotel Dieu Hospital, Kingston, Ontario, Canada
The Department of Anesthesiology,the first Affiliated Hospital of Chongqing Medical University, Chonqqing, Chongqing, China
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Holbæk Sygehus, Holbæk, Denmark
Nordsjællands Hospital, Hillerød, Denmark
Henry Ford Health System, Detroit, Michigan, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
Women's College Hospital, Toronto, Ontario, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.